

FIG. 1





Figure 2
A



B






Figure 3

B16F10 Melanoma:

A




B




Glioma 261:

C




D




Cloudman Melanoma:

E




F



Days post tumor cell injection

Figure 4
A



B





Figure 5
A



B





Figure 6



A






Figure 8
100 μ g DNA:

A




B




C

50 μ g DNA:





D




Days post Tumor Cell Injection

Figure 8 shows the effect of mIFNa pDNA on tumor growth and survival in mice. The top panel (A) shows mean tumor volume (mm³) over time (days post tumor cell injection). The bottom panel (B) shows the percentage survival of mice over time. The legend indicates four groups: control pDNA, 2x/week (filled circles); mIFNa pDNA, 2x/week (open diamonds); mIFNa pDNA, 1x/week (open circles); and mIFNa pDNA, 1x/every other week (open triangles). The data shows that mIFNa pDNA treatment significantly reduces tumor growth and increases survival compared to control pDNA.


Figure 9
Nude Mice:



C
Beige-Nude Mice:



D




Days post tumor cell injection

Figure 9 shows the mean tumor volume (mm³) and survival percentage for nude mice and beige-nude mice. The data is presented in four panels (A, B, C, D). Panel A shows the mean tumor volume for nude mice, Panel B shows the survival percentage for nude mice, Panel C shows the mean tumor volume for beige-nude mice, and Panel D shows the survival percentage for beige-nude mice. The x-axis for all panels is 'Days post tumor cell injection'.

Figure 10

A



B





Figure 11
A



B





Figure 12
A



B





Figure 13

A Day 1 after DNA:lipid



B Day 3 after DNA:lipid





Figure 14

A Ascites



B Serum






Figure 15
1:1 pDNA:DM/DP

A




B




5:1 pDNA:DM/DP

C




D




pDNA without DM/DP

E




F



Days post tumor cell injection

Figure 16

A



B





Figure 17
A



B





Figure 18

A



B






Figure 19


A




B




C



D



E



F





Figure 20

A



B






Figure 2

Plasmid Name	GENE	Parental Plasmid	Promoter/ Enhancer	Terminator
VR1223	Firefly Lux	VR1012*	CMV	BGH
VR1255	Firefly Lux	VR1223	CMV	mRBG
VR1412	Bacterial LacZ	VR1012*	CMV	BGH
VR1418	Bacterial LacZ	VR1043	RSV	BGH
VR4151	Human IFN- ω	VR1055	CMV	mRBG
VR3301	Human SEAP	VR1012*	CMV	BGH
VR3502	Rat preproinsulin	VR1012*	CMV	BGH
VR2901	Mouse EPO	VR1012*	CMV	BGH
VR1110	Mouse IL-2	VR1012*	CMV	BGH
VR4111	Mouse IFN- α	VR1055	CMV	mRBG
VR4700	Influenza NP	VR1255**	CMV	mRBG
Intermediate plasmids				
VR1012	none	V1J***	CMV	BGH
VR1055	none	VR1255	CMV	mRBG
VR1043	none	VR1343	RSV	BGH

22A
Figure 2A




22B
Figure 2B




[illegible]


22D
Figure 2b






23
Figure 8





24
Figure 4



25
Figure 8





27
Figure 7

28

Figure 8

